Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis

Journal of Molecular Biology

Volumn 312, Issue 5, 2001, Pages 1103-1119

  Kirkitadze, Marina D ^a   Condron, Margaret M ^a   Teplow, David B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Fibrillogenesis; Protein folding

Indexed keywords

AMYLOID BETA PROTEIN;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BETA SHEET; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; ELECTRON MICROSCOPY; FILTRATION; OLIGOMERIZATION; PH; PRIORITY JOURNAL; PROTEIN FOLDING; VASCULAR AMYLOIDOSIS;

EID: 0035812658     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2001.4970     Document Type: Article

References (110)

1. Prevalence and neurobiology of Alzheimer's disease
2. The molecular pathology of Alzheimer's disease
3. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease
4. Translating cell biology into therapeutic advances in Alzheimer's disease
5. Cellular action of β-amyloid precursor protein and its soluble and fibrillogenic derivatives
6. Alzheimer's and prion disease as disorders of protein conformation: Implications for the design of novel therapeutic approaches
7. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse
8. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
9. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
10. 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress
11. 1-42 are potent central nervous system neurotoxins
12. Amyloid β-protein fibrillogenesis - Structure and biological activity of protofibrillar intermediates
13. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
14. Alzheimer's disease - An electron microscopical study
15. Ultrastructural studies in Alzheimer's presenile dementia
16. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
17. The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation
18. Amyloid deposits and amyloidosis: The β-fibrilloses (second of two parts)
19. Amyloid deposits and amyloidosis, the β-fibrilloses (first of two parts)
20. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer's disease indicates cross-β conformation
21. Solid-state NMR as a probe of amyloid fibril structure
22. Structural and kinetic features of amyloid β-protein fibrillogenesis
23. Amyloid fibrillogenesis: Themes and variations
24. Alzheimer's amyloid fibrils: Structure and assembly
25. Aβ(1-40) and Aβ(1-42) adopt remarkably stable monomeric and extended structures in water solution at neutral pH
26. The Alzheimer's peptide Aβ adopts a collapsed coil structure in water
27. The α-helical to β-strand transition in the amino-terminal fragment of the amyloid β-peptide modulates amyloid formation
28. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease
29. Solution structure of amyloid β-peptide(1-40) in a water-micelle environment - Is the membrane-spanning domain where we think it is?
30. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease
31. Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer's disease
32. Synthetic peptide homologous to β-protein from Alzheimer disease forms amyloid-like fibrils in vitro
33. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
34. β-amyloid precursor protein cleavage by a membrane-bound protease
35. α-synuclein in Lewy body disease and Alzheimer's disease
36. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded
37. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
38. Both familial Parkinson disease mutations accelerate α-synuclein aggregation
39. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
40. Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids - Structural analysis using site-directed mutagenesis
41. Solution structure of Syrian hamster prion protein rPrP(90-231)
42. Structure of the recombinant full-length hamster prion protein PrP(29-231): The N terminus is highly flexible
43. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
44. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins
45. Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: A practical guide
46. Determination of protein secondary structure
47. Turns
48. Estimation of protein secondary structure from circular dichroism spectra: Comparison of CONTIN, SELCON, and CDSSTR methods with an expanded reference set
49. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene
50. A novel APP mutation (E693G)- the Arctic mutation, causing Alzheimer's disease with vascular symptoms
51. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, dutch-type
52. An Italian type of HCHWA
53. A de novo designed helix-turn-helix peptide forms nontoxic amyloid fibrils
54. Monitoring protein assembly using quasielastic light scattering spectroscopy
55. Establishing homologies in protein sequences
56. Über einen eigenartigen schweren erkrankungsprozeß der hirnrinde
57. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
58. Amyloid β-protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus
59. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease
60. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides
61. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation
62. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models
63. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
64. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation
65. High-level neuronal expression of Aβ(1-42) in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation
66. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy
67. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry
68. Solid-state NMR determination of the secondary structure of Samia cynthia ricini silk
69. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
70. Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease
71. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome - Implications for initial events in amyloid plaque formation
72. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome
73. Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy
74. Amyloid β-protein fibrillogenesis - Detection of a protofibrillar intermediate
75. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy
76. Kinetics and mechanism of amyloid formation by the prion protein H1 peptide as determined by time-dependent ESR
77. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
78. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease
79. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging
80. Heterogeneity of water-soluble amyloid β-peptide in Alzheimer's disease and Down's syndrome brains
81. Neurotoxic and fibrillogenic properties of aminoterminally modified amyloid β-peptides
82. 692 → Gly) Alzheimer's disease
83. Fibril formation by primate, rodent, and Dutch-hemorrhagic analogues of Alzheimer amyloid β-protein
84. Peptides homologous to the amyloid protein of Alzheimer's disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation
85. Substitutions at codon 22 of Alzheimer's Aβ peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells
86. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
87. 1H NMR of Aβ amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence
88. pH-dependent structural transitions of Alzheimer amyloid peptides
89. Conformation and fibrillogenesis of Alzheimer Aβ peptides with selected substitution of charged residues
90. Rapid induction of Alzheimer Aβ amyloid formation by zinc
91. Transthyretin sequesters amyloid β protein and prevents amyloid formation
92. Zinc-induced Alzheimers Aβ1-40 aggregation is mediated by conformational factors
93. Point substitution in the central hydrophobic cluster of a human β-amyloid congener disrupts peptide folding and abolishes plaque competence
94. Effect of aminoacid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions
95. Racemization: Its biological significance on neuropathogenesis of Alzheimer's disease
96. 23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues
97. Aggregation and fibril formation of mutant or isomerised forms of the amyloid β-proteins
98. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy
99. Temperature-induced conformational changes in amyloid β(1-40) peptide investigated by simultaneous FT-IR microspectroscopy with thermal system
100. Understanding how proteins fold - The lysozyme story so far
101. Stopped-flow circular dichroism
102. The prion folding problem
103. Engineering peptides and proteins that undergo α-to-β transitions
104. Construction of peptides that undergo structural transition from α-helix to β-sheet and amyloid fibril formation by the introduction of N-terminal hydrophobic amino acids
105. Prediction of amyloid fibril-forming proteins
106. On the nucleation and growth of amyloid β-protein fibrils: Detection of nuclei and quantitation of rate constants
107. An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments
108. Determination of protein secondary structure in solution by vacuum ultraviolet circular dichroism
109. Estimation of protein secondary structure from circular dichroism spectra: Inclusion of denatured proteins with native proteins in the analysis